Parabilis Medicines, Inc. Common Stock PBLS
$26.51
+5.91%
at last close
Analyst Consensus
- Consensus Rating
- Buy (4 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $41.25
- Implied Upside
- +55.6%
- Price Target Range
- $40.00 – $45.00
- Analysts (12 mo)
- 4
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-22 | HC Wainwright & Co. |
Initiates coverage on | Buy | $40 |
| 2026-07-06 | GuggenheimMichael Schmidt |
Initiates coverage on | Buy | $40 |
| 2026-07-06 | Leerink PartnersAndrew Berens |
Initiates coverage on | Outperform | $40 |
| 2026-07-06 | B of A SecuritiesTazeen Ahmad |
Initiates coverage on | Buy | $45 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $26.51
- Market Cap
- $3.09 billion
- 52-Week Range
- $22.66 – $42.48
- Average Volume
- 1.39 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.